Patents by Inventor Jay Short
Jay Short has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240044046Abstract: Methods of generating conditionally active proteins that target senescent cells and which are conditionally active in an extracellular environment of a senescent cell. The methods include methods using libraries of evolved proteins and assays employing physiological concentrations of components of bodily fluids. Also disclosed are conditionally active proteins for killing or removing senescent cells, antibodies and antibody fragments, conjugates and pharmaceutical compositions employing these conditionally active proteins and methods for treatment of age-related diseases, conditions or disorders using same. The conditionally active proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety.Type: ApplicationFiled: May 7, 2023Publication date: February 8, 2024Applicant: BioAtla, Inc.Inventor: Jay Short
-
Publication number: 20220282399Abstract: Methods of generating conditionally active proteins that target senescent cells and which are conditionally active in an extracellular environment of a senescent cell. The methods include discovery methods using libraries of evolved proteins and assays employing physiological concentrations of components of bodily fluids. Also disclosed are conditionally active proteins for killing or removing senescent cells, pharmaceutical compositions employing these conditionally active proteins and methods for treatment of age-related diseases, conditions or disorders using same. The conditionally active proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety.Type: ApplicationFiled: May 16, 2022Publication date: September 8, 2022Applicant: BioAtla, Inc.Inventor: Jay Short
-
Publication number: 20180086843Abstract: Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: December 11, 2017Publication date: March 29, 2018Applicant: BIOATLA, LLCInventors: Jay Short, Gerhard Frey, Hwai Wen Chang, William Boyle
-
Patent number: 9856323Abstract: Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: April 26, 2013Date of Patent: January 2, 2018Assignee: BIOATLA, LLCInventors: Jay Short, Gerhard Frey, Hwai Wen Chang, William Boyle
-
Publication number: 20170305986Abstract: The present invention generally relates to novel TGF? protein mutants having surprisingly superior or beneficial or different characteristics as compared to the native TGF? protein. The invention further relates to the use of the novel TGF? protein mutants in methods and kits for treatment of neurological disorders.Type: ApplicationFiled: October 9, 2015Publication date: October 26, 2017Inventors: Matthew KLIPSTEIN, Hwai Wen CHANG, Gerhard FREY, Jay SHORT
-
Publication number: 20150086562Abstract: Anti-CD22 antibodies, including isolated nucleic acids that encode at least one such anti-CD22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof including therapeutic compositions, methods and devices.Type: ApplicationFiled: April 26, 2013Publication date: March 26, 2015Inventors: Jay Short, Gerhard Frey, Hwai Wen Chang, William Boyle
-
Patent number: 8338131Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars.Type: GrantFiled: February 1, 2010Date of Patent: December 25, 2012Assignee: Verenium CorporationInventors: Walter Callen, Toby Richardson, Gerhard Frey, Carl Miller, Martin Kazaoka, Eric Mathur, Jay Short
-
Patent number: 8334125Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.Type: GrantFiled: June 27, 2011Date of Patent: December 18, 2012Assignee: Verenium CorporationInventors: Grace DeSantis, Ellen Chi, Jennifer Ann Chaplin, Aileen Milan, Jay Short, David Weiner, Mark Madden, Darcy Madden, legal representative, Mark Burk, Dan Robertson
-
Patent number: 8173398Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: September 23, 2011Date of Patent: May 8, 2012Assignee: Femta Pharmaceuticals, Inc.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Publication number: 20120006716Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: September 23, 2011Publication date: January 12, 2012Applicant: FEMTA PHARMACEUTICALS, INC.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Patent number: 8062866Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: November 13, 2009Date of Patent: November 22, 2011Assignee: Femta Pharmaceuticals, Inc.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Publication number: 20110229451Abstract: Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.Type: ApplicationFiled: March 5, 2010Publication date: September 22, 2011Applicant: HALOZYME, INC.Inventors: Louis Bookbinder, Gregory Frost, Gilbert Keller, Gerhard Frey, Hwai Chang, Jay Short
-
Patent number: 7993901Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.Type: GrantFiled: December 2, 2009Date of Patent: August 9, 2011Assignee: Verenium CorporationInventors: Grace Desantis, Ellen Chi, Jennifer Ann Chaplin, Aileen Milan, Jay Short, David Weiner, Mark Madden, Marcy Madden, legal representative, Mark Burk, Dan Robertson
-
Publication number: 20100273659Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: February 29, 2008Publication date: October 28, 2010Applicant: VERENIUM CORPORATIONInventors: Grace DeSantis, Jennifer Chaplin, Ellen Chi, Aileen Milan, Jay Short, David Weiner, Mark Madden, Darcy Madden, Dan Robertson
-
Patent number: 7811804Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.Type: GrantFiled: September 9, 2009Date of Patent: October 12, 2010Assignee: Verenium CorporationInventors: Grace DeSantis, Jay Short, Mark Burk, Kelvin Wong, Kelly Chatman, Bob Farwell
-
Publication number: 20100209995Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars.Type: ApplicationFiled: February 1, 2010Publication date: August 19, 2010Applicant: VERENIUM CORPORATIONInventors: Walter Callen, Toby Richardson, Gerhard Frey, Carl Miller, Martin Kazaoka, Eric Mathur, Jay Short
-
Publication number: 20100172968Abstract: A polymer is prepared by self-assembly of a plurality of monomeric polypeptide units. The polymer tends to form a nanotube and is capable of encapsulating a particular drug molecule. Once encapsulated in the polymer of the present invention, the drug molecule may be delivered to a particular location of human body to effectively cure a disease or treat a symptom. Generally, the monomeric polypeptide unit of the present invention has a sequence found in Pyrodictium abyssi, a microorganism that produces an extracellular network having hollow protein tubes, or a sequence substantially identical thereto. The monomeric polypeptide may be mass produced using recombinant biotechnologies and be polymerized into the polymer of the present invention. One or more additional targeting vector may be attached to the monomeric polypeptide unit or the polymer to facilitate the targeting of the drug molecule that may be held there within.Type: ApplicationFiled: October 30, 2007Publication date: July 8, 2010Inventors: Jay Short, Eric J. Mathur, W. Michael Lafferty, Nelson Barton, Kevin Chow
-
Publication number: 20100138945Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: November 13, 2009Publication date: June 3, 2010Applicant: BIOATLA, LLCInventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Patent number: 7459172Abstract: A polymer is prepared by self-assembly of a plurality of monomeric polypeptide units. The polymer tends to form a nanotube and is capable of encapsulating a particular drug molecule. Once encapsulated in the polymer of the present invention, the drug molecule may be delivered to a particular location of human body to effectively cure a disease or treat a symptom. Generally, the monomeric polypeptide unit of the present invention has a sequence found in Pyrodictium abyssi, a microorganism that produces an extracellular network having hollow protein tubes, or a sequence substantially identical thereto. The monomeric polypeptide may be mass produced using recombinant biotechnologies and be polymerized into the polymer of the present invention. One or more additional targeting vector may be attached to the monomeric polypeptide unit or the polymer to facilitate the targeting of the drug molecule that may be held there within.Type: GrantFiled: November 30, 2001Date of Patent: December 2, 2008Assignee: Verenium CorporationInventors: Jay Short, Eric J. Mathur, W. Michael Lafferty, Nelson Barton, Kevin Chow
-
Publication number: 20080227132Abstract: The invention relates to hydrolases and to polypeptides having hydrolase activity. In addition, the invention relates to the use of these hydrolase enzymes in kinetic resolution.Type: ApplicationFiled: January 22, 2008Publication date: September 18, 2008Applicant: Verenium Corporation ( formerly Diversa Corporation )Inventors: Jay Short, Eric J. Mathur, Markus Baumann, Uwe T. Bornscheuer